ArticleLipids in health and disease2026
Untargeted plasma lipidomic profiling associated with pediatric metabolic dysfunction-associated steatohepatitis (MASH).
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAltered lipid metabolism is central to the pathogenesis of MASH, yet lipidomic data in pediatric populations are limited. We conducted a cross-sectional analysis using high-resolution lipidomics to identify lipid alterations associated with pediatric MASH in youth enrolled in NASH CRN studies.
methodsClinical assessments included anthropometrics, lipid panels, liver enzymes, and markers of glucose metabolism. MASLD status was determined by liver biopsy or MRI-PDFF. Plasma untargeted lipidomics was performed using UHPLC-MS/MS. Linear models identified differentially abundant lipids. Network analysis characterized lipid-clinical associations and identified network-informed central lipids to evaluate MASH classification performance.
resultsThe cohort included 102 participants with MASH (29% Zone 1, 19% Zone 3, 52% Definite) and 58 non-MASH participants (29 MASL and 29 controls). Participants were aged 7–18 years; 77% were male and 58% Hispanic, with a mean BMI Z-score of 2.01 ± 0.77. Compared with non-MASH participants, those with MASH had higher BMI Z-scores, waist circumference, liver enzymes, insulin resistance markers, and triglycerides, and lower HDL cholesterol (p < 0.05). Lipidomics analysis revealed higher levels of saturated TG species and lower levels of Cer and SM species in participants with MASH (p < 0.05). Network analysis showed greater centrality of insulin resistance markers (fasting insulin, HOMA-IR) among participants with MASH, whereas non-MASH participant networks exhibited broader lipid-clinical connectivities. Adding central lipids [TG(12:0_16:0_18:2), SM(d32:3), TG(50:5)] with a high Eigenvector Centrality Score (ECS) significantly improved MASH classification performance.
conclusionsPediatric MASH was associated with plasma lipid remodeling, and network-derived central lipids improved MASH classification performance. These findings highlight the potential of lipid signatures for the noninvasive diagnosis of pediatric MASH and warrant validation in independent, longitudinal cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.